Advanced search
Publication Cover
mAbs Volume 9, 2017 - Issue 7
Submit an article Journal homepage
4,271
Views
22
CrossRef citations to date
0
Altmetric
Report

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization

Di ZhangJanssen Research and Development, L.L.C., Spring House, PA, USACorrespondence[email protected] [email protected]
,
Anthony A. ArmstrongJanssen Research and Development, L.L.C., Spring House, PA, USA
,
Susan H. TamJanssen Research and Development, L.L.C., Spring House, PA, USAORCID Iconhttp://orcid.org/0000-0002-4941-8235
ORCID Icon,
Stephen G. McCarthyJanssen Research and Development, L.L.C., Spring House, PA, USAORCID Iconhttp://orcid.org/0000-0001-8991-2636
ORCID Icon,
Jinquan LuoJanssen Research and Development, L.L.C., Spring House, PA, USA
,
Gary L. GillilandJanssen Research and Development, L.L.C., Spring House, PA, USAORCID Iconhttp://orcid.org/0000-0001-7394-1846
ORCID Icon &
Mark L. ChiuJanssen Research and Development, L.L.C., Spring House, PA, USACorrespondence[email protected] [email protected]
 show all
Pages 1129-1142 | Received 03 May 2017, Accepted 18 Jul 2017, Published online: 24 Aug 2017

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yanli Yang, Sherry H. Yeh, Shravan Madireddi, Wadim L. Matochko, Chen Gu, Patricia Pacheco Sanchez, Mark Ultsch, Gladys De Leon Boenig, Seth F. Harris, Brandon Leonard, Suzie J. Scales, Jing W. Zhu, Erin Christensen, Julie Q. Hang, Randall J. Brezski, Scot Marsters, Avi Ashkenazi, Siddharth Sukumaran, Henry Chiu, Rafael Cubas, Jeong M. Kim & Greg A. Lazar. (2019) Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. mAbs 11:6, pages 996-1011.
Read now
Di Zhang, Brian Whitaker, Mehabaw G. Derebe & Mark L. Chiu. (2018) FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody. mAbs 10:3, pages 463-475.
Read now

Articles from other publishers (20)

Kodchakorn Mahasongkram, Kantaphon Glab-ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang & Wanpen Chaicumpa. (2023) Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines 11:12, pages 1826.
Crossref
Yue Zhang, Gui Zhao, Yi‐Fang Chen, Shi‐Kun Zhou, Yue Wang, Yi‐Qun Sun, Song Shen, Cong‐Fei Xu & Jun Wang. (2023) Engineering nano‐clustered multivalent agonists to cross‐link TNF receptors for cancer therapy. Aggregate.
Crossref
Osman Dadas, Ayse Ertay & Mark S. Cragg. (2023) Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives. Frontiers in Immunology 14.
Crossref
Harkamal S. Jhajj, Timon S. Lwo, Emily L. Yao & Peter M. Tessier. (2023) Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. Trends in Molecular Medicine 29:1, pages 48-60.
Crossref
Simone C. Oostindie, Greg A. Lazar, Janine Schuurman & Paul W. H. I. Parren. (2022) Avidity in antibody effector functions and biotherapeutic drug design. Nature Reviews Drug Discovery 21:10, pages 715-735.
Crossref
Jing Zhang, Xiaoyong Jiang, Han Gao, Fei Zhang, Xin Zhang, Aiwu Zhou, Ting Xu & Haiyan Cai. (2022) Structural Basis of a Novel Agonistic Anti-OX40 Antibody. Biomolecules 12:9, pages 1209.
Crossref
Luyan Liu, Yi Wu, Kaiyan Ye, Meichun Cai, Guanglei Zhuang & Jieyi Wang. (2022) Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking. Frontiers in Pharmacology 13.
Crossref
John S. Schardt, Harkamal S. Jhajj, Ryen L. O'Meara, Timon S. Lwo, Matthew D. Smith & Peter M. Tessier. (2022) Agonist antibody discovery: Experimental, computational, and rational engineering approaches. Drug Discovery Today 27:1, pages 31-48.
Crossref
Valentina Ceglia, Sandra Zurawski, Monica Montes, Aurélie Bouteau, Zhiqing Wang, Jerome Ellis, Botond Z. Igyártó, Yves Lévy & Gerard Zurawski. (2021) Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties. The Journal of Immunology 207:8, pages 2060-2076.
Crossref
Seung Hyun Kang & Chang-Han Lee. (2021) Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy. Biotechnology and Bioprocess Engineering 26:3, pages 295-311.
Crossref
Meng Li, Lan Wang, Chuanfei Yu & Junzhi Wang. (2021) Development of a robust reporter gene assay for measuring the bioactivity of OX40‐targeted therapeutic antibodies. Luminescence 36:4, pages 885-893.
Crossref
Yongli Yang, Xiaojuan Chai, Wenfang Xin, Dongxu Wang, Chaohui Dai, Feng Qian & Teddy Yang. (2021) Generation and characterization of a high‐affinity chimeric anti‐OX40 antibody with potent antitumor activity. FEBS Letters 595:11, pages 1587-1603.
Crossref
Zhihui Kuang, Pu Pu, Min Wu, Zhihai Wu, Li Wang, Yiming Li, Shaofei Zhang, Hua Jing, Weiwei Wu, Bingliang Chen & Junjian Liu. (2020) A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment. Molecular Cancer Therapeutics 19:12, pages 2564-2574.
Crossref
Zhihui Kuang, Hua Jing, Zhihai Wu, Jie Wang, Yiming Li, Haiqing Ni, Pan Zhang, Weiwei Wu, Min Wu, Shuaixiang Zhou, Xuan Qiu, Dongdong Wu, Bianka Prinz, Hemanta Baruah, Bingliang Chen, Michael Yu & Junjian Liu. (2020) Development and characterization of a novel anti-OX40 antibody for potent immune activation. Cancer Immunology, Immunotherapy 69:6, pages 939-950.
Crossref
Jürgen Strasser, Rob N. de Jong, Frank J. Beurskens, Janine Schuurman, Paul W. H. I. Parren, Peter Hinterdorfer & Johannes Preiner. (2019) Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen Recognition. ACS Nano 14:3, pages 2739-2750.
Crossref
Mark L. Chiu, Dennis R. Goulet, Alexey Teplyakov & Gary L. Gilliland. (2019) Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 8:4, pages 55.
Crossref
Jürgen Strasser, Rob N. de Jong, Frank J. Beurskens, Guanbo Wang, Albert J. R. Heck, Janine Schuurman, Paul W. H. I. Parren, Peter Hinterdorfer & Johannes Preiner. (2019) Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces. Nano Letters 19:7, pages 4787-4796.
Crossref
Kenta Haraya, Tatsuhiko Tachibana & Tomoyuki Igawa. (2019) Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metabolism and Pharmacokinetics 34:1, pages 25-41.
Crossref
Ming Liu & Fukun Guo. (2018) Recent updates on cancer immunotherapy. Precision Clinical Medicine 1:2, pages 65-74.
Crossref
Patrick A. Mayes, Kenneth W. Hance & Axel Hoos. (2018) The promise and challenges of immune agonist antibody development in cancer. Nature Reviews Drug Discovery 17:7, pages 509-527.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.